Wei Wang, Miao He, Wenyong Huang
Journal: Diabetes research and clinical practice 2016;120():40-6
PMID: 27505625
AIMS
The relationship between monocyte chemoattractant protein-1 (MCP-1) 2518 A/G polymorphism and diabetic retinopathy (DR) attracted intense interest recently, but the reported results are controversial. A meta-analysis was performed to assess the MCP-1 polymorphism associated with DR susceptibility in type 2 diabetes mellitus.
METHODS
Eligible studies were identified from PubMed, Embase, Web of science, Chinese Biomedical database, and references of retrieved articles. Pooled odds ratios (ORs) with their 95% confidence intervals (95%CI) were calculated by fixed or random-effects models.
RESULTS
Six studies involving 3415 patients without DR and 3468 with any DR were included in the final meta-analysis. Each 5 studies evaluated the associations of MCP-1 polymorphism and any DR and proliferative DR (PDR), respectively. Meta-analysis in fixed model demonstrated a significant association between MCP-1 polymorphism and any DR under the homozygous model (OR=1.36; 95%CI: 1.15-1.62, P<0.001), heterozygous model (OR=1.20; 95%CI: 1.02-1.42, P=0.031), dominant model (OR=1.28; 95%CI: 1.10-1.50, P=0.002), recessive model (OR=1.17; 95%CI: 1.05-1.31, P=0.004), and allelic model (OR=1.16; 95%CI: 1.07-1.25, P<0.001). Furthermore, a significant association of MCP-1 polymorphism and DR progression from non-proliferative DR to proliferative DR was identified under heterozygous model (OR=1.45; 95%CI: 1.04-2.02, P=0.030). Sensitivity analyses did not draw different findings.
CONCLUSIONS
Meta-analysis of existing data suggested that MCP-1 2518 A/G polymorphism affected the risk of presence and progression of DR in type 2 diabetes mellitus.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
Medical:
Other Literature Sources:
Miscellaneous:
Research Materials:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.